CanWell Pharma Announces FDA Clearance for New Cancer Drug

Got story updates? Submit your updates here. ›

CanWell Pharma, a Massachusetts-based biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its novel cancer drug candidate CAN016. This dual-payload antibody-drug conjugate (ADC) is designed to target the HER2 protein, which is overexpressed in certain types of breast and gastric cancers.

Why it matters

The clearance of the IND application by the FDA is a significant milestone for CanWell, as it allows the company to proceed with clinical trials for CAN016. If successful, this new ADC therapy could provide an important new treatment option for patients with HER2-positive cancers, which are often aggressive and difficult to treat.

The details

CAN016 is an ADC that combines an antibody targeting the HER2 protein with two different cytotoxic payloads. This dual-payload approach is designed to enhance the drug's efficacy by simultaneously attacking the cancer cells through multiple mechanisms. The IND clearance enables CanWell to initiate Phase 1 clinical trials to evaluate the safety, tolerability, and preliminary efficacy of CAN016 in patients with advanced HER2-positive solid tumors.

• CanWell Pharma announced the FDA clearance of the IND for CAN016 on April 2, 2026.

What’s next

With the IND clearance, CanWell Pharma will now proceed to initiate Phase 1 clinical trials to evaluate the safety and efficacy of CAN016 in patients with advanced HER2-positive solid tumors.